P3-315 Synaptic AMPA receptor dysfunction: a mechanism for cognitive decline in type-1-diabetic rats

2004 ◽  
Vol 25 ◽  
pp. S444-S445
Author(s):  
Thirumalini Vaithianathan ◽  
Deepa Bedi ◽  
Kanju M. Patrick ◽  
Kodeeswaran Parameshwaran ◽  
Lori L. McMahon ◽  
...  
2018 ◽  
Vol 46 (4) ◽  
pp. 1668-1682 ◽  
Author(s):  
Yu Zhou ◽  
Siheng Lian ◽  
Jin Zhang ◽  
Donghai Lin ◽  
Caihua Huang ◽  
...  

Background/Aims: Mitochondrial perturbation is a well-established cause of cognitive decline, but as yet it is unclear how mitochondria-associated neuronal abnormalities in type 1 diabetic (T1DM) brain contribute to cognitive decline. Methods: The streptozotocin (STZ)-induced mouse model of T1DM was used. The Morris water maze test was applied to assess the effect of T1DM on learning and memory. We detected changes in mitochondrial morphology, function and dynamics. Furthermore, we employed metabolomic analysis to reveal the underlying mechanisms of mitochondrial perturbation which contribute to cognitive decline. Results: Our results show that T1DM impairs mitochondrial dynamics, morphology and function in neurons, associated with a decline in cognitive ability. Metabolomic analyses revealed that T1DM mainly affects metabolic pathways involved in mitochondrial energy failure and impairs the antioxidative system. Conclusion: These results lay the basis for understanding the underlying mitochondria-associated causes of T1DM-associated cognitive decline and may provide a potential treatment strategy for this condition in future.


2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Iwona Chmiel-Perzyńska ◽  
Adam Perzyński ◽  
Bartosz Olajossy ◽  
Paulina Gil-Kulik ◽  
Janusz Kocki ◽  
...  

Patients with diabetes mellitus (DM) type 1 and 2 are at a higher risk of cognitive decline and dementia; however, the underlying pathology is poorly understood. Kynurenic acid (KYNA), endogenous kynurenine metabolite, displays pleiotropic effects, including a blockade of glutamatergic and cholinergic receptors. Apart from well-known glial origin, kynurenic acid is robustly synthesized in the endothelium and its serum levels correlate with homocysteine, a risk factor for cognitive decline. Studies in an experimental DM model suggest that a selective, hippocampal increase of the kynurenic acid level may be an important factor contributing to diabetes-related cognitive impairment. The aim of this study was to assess the effects of chronic, four-week administration of losartan, angiotensin receptor blocker (ARB), on the brain KYNA in diabetic rats. Chromatographic and rt-PCR techniques were used to measure the level of KYNA and the expression of genes encoding kynurenine aminotransferases, KYNA biosynthetic enzymes, in the hippocampi of rats with streptozotocin-induced DM, treated with losartan. The effect of losartan on KYNA synthesis de novo was also evaluated in vitro, in brain cortical slices. The hippocampal increase of KYNA content occurred in diabetic rats treated and nontreated with insulin. Losartan did not affect KYNA levels when administered per se to naïve or diabetic animals but normalized KYNA content in diabetic rats receiving concomitantly insulin. The expression of CCBL1 (kat 1), AADAT (kat 2), and KAT3 (kat 3) genes did not differ between analyzed groups. Low concentrations of losartan did not affect KYNA production in vitro. The neuroprotective effect of ARBs in diabetic individuals may be, at least partially, linked to modulation of KYNA metabolism. The ability of ARB to modulate synthesis of KYNA in diabetic brain does not seem to result from changed expression of genes encoding KATs. We propose possible involvement of angiotensin AT4 receptors in the observed action of losartan.


Cell Reports ◽  
2020 ◽  
Vol 32 (13) ◽  
pp. 108207
Author(s):  
Xiao Wei ◽  
Zongshi Lu ◽  
Li Li ◽  
Hexuan Zhang ◽  
Fang Sun ◽  
...  

Author(s):  
Abbas Alimoradian ◽  
Fatemeh Samimi ◽  
Hadise Aslfalah ◽  
Seied Amirhossein Latifi ◽  
Mehdi Salehi ◽  
...  

Abstract Objectives Pain associated with various underlying pathologies is a major cause of morbidity and diminished life quality in diabetic patients. Effective control of pain requires the use of analgesics with the best efficacy and with minimal side effects. Therefore, our aim in this study was to investigate the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on pain in diabetic rats. Methods In this study, we investigated the analgesic effects of drugs belonging to three different classes of NSAIDs in a rat model of diabetes. Four diabetic groups received normal saline, diclofenac, piroxicam and ketorolac, respectively, and four non-diabetic groups received normal saline, diclofenac, piroxicam and ketorolac. Type 1 diabetes was induced in rats by a single injection of streptozotocin (60 mg/kg bw). Formalin (50 µL of 2.5%) nociception assay was used to examine the effect of treatment with diclofenac, piroxicam and ketorolac on acute and chronic pain in healthy and diabetic rats. Results Piroxicam showed significant analgesic effects both in the acute phase of pain (5–10 min after injection of formalin into the left hind paw), and in the chronic phase (20–60 min after formalin injection) in healthy as well as diabetic rats. Diclofenac and ketorolac also reduced pain scores in healthy rats. However, these two drugs failed to diminish pain in diabetic rats. Conclusion Our data point for better efficacy of piroxicam in controlling pain in diabetes.


2012 ◽  
Vol 1 (1) ◽  
pp. 57-65 ◽  
Author(s):  
Mingming Huang ◽  
Lifeng Gao ◽  
Liqin Yang ◽  
Fuchun Lin ◽  
Hao Lei

2014 ◽  
Vol 4 ◽  
pp. S421-S425 ◽  
Author(s):  
Hassan Ahmadvand ◽  
Akram Noori ◽  
Maryam Ghasemi Dehnoo ◽  
Shahrokh Bagheri ◽  
Rooh Angiz Cheraghi
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document